Saida, Takahiko
Hao, Qi
Kanda, Michihiro
Tani, Yumiko
Funding for this research was provided by:
Biogen Japan Ltd. (N/A)
Article History
Received: 14 December 2022
Accepted: 20 June 2023
First Online: 29 August 2023
Declarations
:
: The study was conducted in accordance with the relevant Japanese regulations and guidelines for human medical research and the Declaration of Helsinki. The study underwent review by the ethics committee of the participating medical institution. Only data from patients who provided written informed consent were included. The study was conducted in accordance with the relevant Japanese regulations and guidelines for human medical research and the Declaration of Helsinki. The study underwent review by the ethics committee of the participating medical institution. Only data from patients who provided written informed consent were included. Written informed consent was obtained from all patients or their proxy (close relative) prior to data being collected; only data from consenting patients were included in this chart review.
: Not applicable.
: The research was conducted from a medical perspective based on a joint research agreement with Biogen Japan Ltd. TS has served as a medical advisor and has received honoraria for delivering scientific lectures for Alexion Pharmaceuticals Inc., Biogen, Bayer, Eisai Co., Mitsubishi-Tanabe Pharmaceuticals, and Novartis. MK and YT are employees of Biogen and hold stock/stock options in Biogen. QH has nothing to declare.